Astrocyte Pharmaceuticals uses astrocytes to develop neuroprotective therapies for treatment of traumatic brain injuries, concussions, stroke, and neurodegenerative disease. Astrocytes and other glial cells play vital functions in brain cell maintenance and repair, making them great therapeutic targets. Astrocyte Pharma is a clinical-stage biopharma company. Co-founders William S. Korinek and James D. Lechleiter started Astrocyte Pharma in 2014.

Astrocyte Pharmaceuticals

 Ted Liston on LinkedIn: Congratulations to our Astrocyte team and all of our collaborators around… 


				Senator Chris Murphy Highlights Groton’s Astrocyte Pharmaceuticals As “Innovator Of The Month”			


				Astrocyte Pharmaceuticals Presents Update on AST-004 Clinical Program at 2022 Military Health System Research Symposium			

The Race Is on for a 'Concussion Pill' as New NFL Season Begins - Bleacher Report

“The Race Is on for a ‘Concussion Pill’ as New NFL Season Begins”


				Astrocyte Pharmaceuticals Announces Appointment of Christine Gallagher to Board of Directors			

CT Biotech Firm Working Drug to Treat Stroke, Brain Injuries - JEMS (Journal of Emergency Medical Services)

 Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004 

Astrocyte starts extended infusion Phase lB brain injuries therapy trial - Clinical Trials Arena

This Biotech Fights Alzheimer’s Disease by Targeting Support Brain Cells - Labiotech.eu

Tune in to the latest podcast with Timothy Dougherty and BiotechInsights to hear the story behind the founding of Astrocyte Pharmaceuticals, the promising potential of the AST-004 therapeutic for treating #stroke and #TBI, insights into the evolving world of #neuroprotection R&D, and valuable advice for aspiring scientific founders!


				Astrocyte Pharmaceuticals Awarded Major Grant to Further Develop Promising Treatment for Brain Injury			


				Alzheimer’s Drug Discovery Foundation Joins Astrocyte Pharmaceuticals’ $6M+ Pre-Series B Financing Round to Expand Development of Cerebroprotectant AST-004			

Preventing permanent brain injury after stroke

“A Pill for Concussions Remains a Brain-Busting Challenge”

We’re excited to share our latest advances in brain injury treatment! Learn how we’re advancing neuroprotection for #stroke and #TBI #concussion .

San Antonio researchers developing brain injury treatment


				Astrocyte Pharmaceuticals Announces Publication in the Journal Stroke of Results Supporting Advancement of AST-004 into in the Clinic			

“Game-Changing Neuroprotection: Astrocyte Pharmaceuticals Breakthrough in Brain Injury Treatment”

“To Curb Brain Damage, Astrocyte Pharmaceuticals Energizes Cells”

Liston T. et al. 2022


				MTEC Awards $3M to Astrocyte Pharmaceuticals for Clinical Study of AST-004			

 Sharyn Rossi on LinkedIn: Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational… 

Game On for Concussion Therapies - Genetic Engineering & Biotechnology News

S.A. scientist’s brain injury drug being tested in humans - San Antonio Express-News

Game On for Concussion Therapies

An interview with Dr. Liston regarding the research is available online

Meet with Astrocyte Pharmaceuticals at #ASCPT2024! Astrocyte’s Lisa Manna, MBA RN will be presenting our poster with QPS Holdings, LLC on the Phase 1B trial of AST-004, and its innovative use of serial CSF collection!

“Pursuing Concussion’s Cure” 


				Lisa Manna Joins Astrocyte Pharmaceuticals as Vice President of Clinical Development Operations			

Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004 - Yahoo Finance

First-in-Human Phase I Clinical Trial of the Adenosine A1R/A3R Agonist AST-004 in Healthy Subjects - AHA Journals

Brain injury therapy advancing toward human studies


				Astrocyte Pharmaceuticals Announces Theodore Liston, Ph.D., Vice President of Research, as Recipient of the 2022 Innovation and Progress Award from the Journal Stroke			

Another milestone for Astrocyte Pharmaceuticals! We look forward to advancing our neuroprotectant AST-004 to Phase 2 clinical studies in the US! https://lnkd.in/eGk-9Qsk    #biotech #stroke #tbi #concussion  U.S. Army Medical Research and Development Command, MTEC | Medical Technology Enterprise Consortium, BrightFocus Foundation

 Astrocyte Pharmaceuticals Announces Theodore Liston, Ph.D., Vice President of Research, as Recipient of the 2022 Innovation and Progress Award from the Journal Stroke 


				Astrocyte Pharmaceuticals Announces FDA Clearance of its Investigational New Drug Application for AST-004			

Innovative new brain injury treatment tested in 1st human subject, may hold promise for patients with Alzheimer’s Disease with Dr. James Lechleiter and Dr. William Korinek

Novel brain injury treatment tested in 1st human subject - UT Health San Antonio

Innovator of the Month!

New broad-ranging podcast conversation between Astrocyte Pharmaceuticals' CEO William Korinek and Vial's Amy Del Medico - click to learn more about #astrocytes, #neuroprotection and the advancement of new potential treatments!

Traumatic Brain Injury Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update - GlobalData

Astrocyte's successful Phase 1 First-in-Human Trial of AST-004 now published in the journal Stroke by Lisa Manna, MBA RN, Juan Hernandez, Dawn Hunt, Dr. Géza Lakner, Mark Matson, Rusty Poe, Ph.D., PMP, Robert Lancey, and Ted Liston! https://lnkd.in/ekdZa6SU #stroke #TBI

Astrocyte Pharmaceuticals

Business:

Drug notes:

About: